.png){kind=logo}
Investigating the efficacy, safety, and tolerability of ML-004 in adolescents and adults with autism
We are working with Maplight and other sites around Australia, Canada, and the United States, to investigate the safety, tolerability, and efficacy of a pharmaceutical therapy called ML-004.
​
We are looking to find out whether ML-004
might address the characteristics of autism that can make social interaction challenging.
Recruitment
To be eligible, participants must be:
-
Be aged 12 - 45 years old (currently, we are recruiting adults aged 18 years and older but we will be recruiting adolescents aged 12 - 17 later in 2023)
-
Have an autism diagnosis
-
Have a relative, housemate, friend, or other study partner to assist during the study and attend clinic visits
​
There are additional requirements for participation. The study staff will explain the complete list of requirements.
​
This study is currently OPEN. Register your interest below. ​